Organon & Co. (OGN) Reaches 52-Week High Following $11.75-Billion Merger with Sun Pharmaceuticals

Organon & Co. (OGN) reached a 52-week high after confirming a $11.75-billion merger with Sun Pharmaceuticals. The stock rose 16.87% to $13.16, with the deal valued at $14 per share. The merger is expected to close in early 2027, pending shareholder approval.

By Angelica Ballesteros Tue, April 28, 2026 at 5:16 AM GMT+3 2 min read · Yahoo Finance · April 28, 2026, 02:16 UTC

Tickers: $OGN

Topics: corporate strategy merger pharmaceutical industry stock price movement

Read the full article at Yahoo Finance

More World news

Hugging Face CEO Reaffirms Commitment to Open-Source AI Following Nvidia CEO Jensen Huang's Departure TechCrunch · November 12, 2026, 17:36 UTC
Marimed Reports Record $44.2M Quarterly Revenue and Targets 2027 New York Launch Seeking Alpha · November 12, 2026, 17:30 UTC
Nebius Group Reports Massive Q3 2026 Revenue Growth Driven by AI Cloud Expansion Motley Fool · November 12, 2026, 17:29 UTC
Reagan Institute Launches Society of Fellows to Support Early Career Scholars PR Newswire · November 12, 2026, 17:32 UTC
Global Asset Management Group Signs LOI for $100 Million Affordable Housing Portfolio in Washington, D.C. PR Newswire · November 12, 2026, 17:30 UTC
U.S. Air Conditioner and Heat Pump Shipments Increase 27.3% in September Seeking Alpha · November 12, 2026, 17:27 UTC
Nvidia CEO Jensen Huang Resigns Amid Intelligence Probe Seeking Alpha · November 12, 2026, 17:27 UTC
Oklo and Centrus Energy Sign Multi-Year HALEU Fuel Supply Agreements for Ohio Nuclear Campus Seeking Alpha · November 12, 2026, 17:28 UTC
IRS Announces Increased 401(k) Contribution Limits for 2027 CNBC · November 12, 2026, 17:23 UTC
Bit Digital Announces $865 Million Contract and Commencement of 40MW Billing Seeking Alpha · November 12, 2026, 17:20 UTC